@Article{biocell.2019.07018,
AUTHOR = {Ana Laura CIMADOR, Emeli Luciana GALANTE, Lucila Ibel MUÑOZ, Patricia Silvia ROMANO, Antonella Denisse LOSINNO, María Cristina VANRELL},
TITLE = {<i>Trypanosoma rangeli:</i> growth in mammalian cells <i>in vitro</i> and action of a repositioned drug (17-AAG) and a natural extract (<i>Artemisia sp</i>. essential oil)},
JOURNAL = {BIOCELL},
VOLUME = {43},
YEAR = {2019},
NUMBER = {1},
PAGES = {13--20},
URL = {http://www.techscience.com/biocell/v43n1/33353},
ISSN = {1667-5746},
ABSTRACT = {<i>Trypanosoma rangeli</i> and <i>T. cruzi</i> are both parasitic unicellular species that infect humans. Unlike <i>T. cruzi</i>,
the causative agent of Chagas disease, <i>T. rangeli</i> is an infective and non-pathogenic parasite for humans, but pathogenic
for vectors from the Rhodnius genus. Because both species can coexist in different hosts and overlap their infective
cycles but very little is known about the infection of <i>T. rangeli</i> in mammalian cells, we decided to characterize both the
development of this parasite in cell culture and the effect of therapeutic agents with potential trypanocidal action on
it. We found that <i>T. rangeli</i> exhibits a cycle of infection in Vero cells similar to that for <i>T. cruzi</i> and that the repurposed
drug, 17-AAG, and the natural extract <i>Artemisia sp</i>. essential oil produce a toxic effect on epimastigotes showing
a trypanocidal action from the fifth day of culture. Both treatments also affected the infection of trypomastigotes
and reduced the capacity of replication of amastigotes of <i>T. rangeli.</i> Since <i>T. cruzi / T. rangeli</i> coinfection cases have
been reported, the finding of drugs with potential activity against both species could be significant in the future.
Furthermore, studies of susceptibility of both species to drugs could also help to know the different mechanisms of
pathogenicity in humans displayed by <i>T. cruzi</i> that are absent in <i>T. rangeli</i>},
DOI = {10.32604/biocell.2019.07018}
}